Scientists test two forms of cholesterol drug in healthy volunteers

NCT ID NCT07422285

Recruiting now Knowledge-focused Sponsor: Amgen Source: ClinicalTrials.gov ↗

Summary

This early-stage study aims to understand how two different versions of the cholesterol-lowering drug evolocumab are absorbed and processed by the body. It will involve 400 healthy adults who will receive a single dose. The main goal is to compare how much of each drug version gets into the bloodstream and how long it stays there.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fortrea Clinical Research Unit - Dallas

    RECRUITING

    Dallas, Texas, 75247, United States

  • Fortrea Clinical Research Unit - Daytona Beach

    RECRUITING

    Daytona Beach, Florida, 32117-5116, United States

  • Fortrea Clinical Research Unit Inc. - Madison

    RECRUITING

    Madison, Wisconsin, 53704-2526, United States

  • QPS Bio-Kinetic

    RECRUITING

    Springfield, Missouri, 65802-4842, United States

Conditions

Explore the condition pages connected to this study.